{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:22Z","timestamp":1790821942985,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40265-025-02235-4","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:47:28Z","timestamp":1758620848000},"page":"1413-1428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3318-9482","authenticated-orcid":false,"given":"Richard J.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0685-1543","authenticated-orcid":false,"given":"Matthew","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-2301","authenticated-orcid":false,"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2235_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.13640","volume":"107","author":"SJ Richards","year":"2021","unstructured":"Richards SJ, Painter D, Dickinson AJ, Griffin M, Munir T, Arnold L, et al. The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: a retrospective analysis of the UK\u2019s population-based haematological malignancy research network 2004\u20132018. Eur J Haematol. 2021;107:211\u20138.","journal-title":"Eur J Haematol"},{"key":"2235_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253\u20138.","journal-title":"N Engl J Med"},{"key":"2235_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1172\/JCI114172","volume":"84","author":"MH Holguin","year":"1989","unstructured":"Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Investig. 1989;84:7\u201317.","journal-title":"J Clin Investig"},{"key":"2235_CR4","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","volume":"144","author":"SA Rollins","year":"1990","unstructured":"Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b\u20139. J Immunol. 1990;144:3478\u201383.","journal-title":"J Immunol"},{"key":"2235_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.hoc.2015.02.001","volume":"29","author":"JC Varela","year":"2015","unstructured":"Varela JC, Tomlinson S. Complement: an overview for the clinician. Hematol Oncol Clin N Am. 2015;29:409\u201327.","journal-title":"Hematol Oncol Clin N Am"},{"key":"2235_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2141.1992.tb08151.x","volume":"80","author":"P Hillmen","year":"1992","unstructured":"Hillmen P, Hows JM, Luzzatto L. Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1992;80:399\u2013405.","journal-title":"Br J Haematol"},{"key":"2235_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1182\/blood.V84.1.309.309","volume":"84","author":"H Nakakuma","year":"1994","unstructured":"Nakakuma H, Nagakura S, Horikawa K, Hidaka M, Kawaguchi T, Iwamoto N, et al. Interleukin-2-dependent T-cell lines established from paroxysmal nocturnal hemoglobinuria patients. Blood. 1994;84:309\u201314.","journal-title":"Blood"},{"key":"2235_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood.V76.6.1181.1181","volume":"76","author":"J Schubert","year":"1990","unstructured":"Schubert J, Uciechowski P, Delany P, Tischler HJ, Kolanus W, Schmidt RE. The PIG-anchoring defect in NK lymphocytes of PNH patients. Blood. 1990;76:1181\u20137.","journal-title":"Blood"},{"key":"2235_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1083\/jcb.121.5.987","volume":"121","author":"J Vidugiriene","year":"1993","unstructured":"Vidugiriene J, Menon AK. Early lipid intermediates in glycosyl-phosphatidylinositol anchor assembly are synthesized in the ER and located in the cytoplasmic leaflet of the ER membrane bilayer. J Cell Biol. 1993;121:987\u201396.","journal-title":"J Cell Biol"},{"key":"2235_CR10","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1073\/pnas.82.9.2980","volume":"82","author":"ME Medof","year":"1985","unstructured":"Medof ME, Kinoshita T, Silber R, Nussenzweig V. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci USA. 1985;82:2980\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2235_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058\u201366.","journal-title":"N Engl J Med"},{"key":"2235_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2141.1973.tb01657.x","volume":"24","author":"WF Rosse","year":"1973","unstructured":"Rosse WF. Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1973;24:327\u201342.","journal-title":"Br J Haematol"},{"key":"2235_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2141.1974.tb06652.x","volume":"28","author":"WF Rosse","year":"1974","unstructured":"Rosse WF, Adams JP, Thorpe AM. The population of cells in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis: significance and mechanism of increased immune lysis. Br J Haematol. 1974;28:181\u201390.","journal-title":"Br J Haematol"},{"key":"2235_CR14","first-page":"5755","volume":"4","author":"S Langemeijer","year":"2020","unstructured":"Langemeijer S, Schaap C, Preijers F, Jansen JH, Blijlevens N, Inoue N, et al. Paroxysmal nocturnal hemoglobinuria caused by CN-LOH of constitutional PIGB mutation and 70-kbp microdeletion on 15q. Blood Adv. 2020;4:5755\u201361.","journal-title":"Blood Adv"},{"key":"2235_CR15","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1182\/blood-2014-09-598813","volume":"124","author":"JR Costa","year":"2014","unstructured":"Costa JR, Caputo VS, Makarona K, Layton DM, Roberts IAG, Almeida AM, et al. Cell-type\u2013specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency. Blood. 2014;124:3151\u20134.","journal-title":"Blood"},{"key":"2235_CR16","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1172\/JCI123501","volume":"129","author":"B H\u00f6chsmann","year":"2019","unstructured":"H\u00f6chsmann B, Murakami Y, Osato M, Knaus A, Kawamoto M, Inoue N, et al. Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. J Clin Investig. 2019;129:5123\u201336.","journal-title":"J Clin Investig"},{"key":"2235_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/nm1410","volume":"12","author":"AM Almeida","year":"2006","unstructured":"Almeida AM, Murakami Y, Layton DM, Hillmen P, Sellick GS, Maeda Y, et al. Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nat Med. 2006;12:846\u201350.","journal-title":"Nat Med"},{"key":"2235_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/oxfordjournals.jbchem.a021746","volume":"122","author":"T Kinoshita","year":"1997","unstructured":"Kinoshita T, Ohishi K, Takeda J. GPI-anchor synthesis in mammalian cells: genes, their products, and a deficiency. J Biochem. 1997;122:251\u2013725.","journal-title":"J Biochem"},{"key":"2235_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2013-01-481499","volume":"122","author":"PM Krawitz","year":"2013","unstructured":"Krawitz PM, H\u00f6chsmann B, Murakami Y, Teubner B, Kr\u00fcger U, Klopocki E, et al. A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT. Blood. 2013;122:1099\u2013100.","journal-title":"Blood"},{"key":"2235_CR20","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/sj.leu.2402694","volume":"16","author":"DJ Araten","year":"2002","unstructured":"Araten DJ, Bessler M, McKenzie S, Castro-Malaspina H, Childs BH, Boulad F, et al. Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones. Leukemia. 2002;16:2243\u20138.","journal-title":"Leukemia"},{"key":"2235_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2006-01-0256","volume":"108","author":"DJ Araten","year":"2006","unstructured":"Araten DJ, Luzzatto L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006;108:734\u20136.","journal-title":"Blood"},{"issue":"Supplement 2","key":"2235_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/BF03165111","volume":"76","author":"NS Young","year":"2002","unstructured":"Young NS, Maciejewski JP, Sloand E, Chen G, Zeng W, Risitano A, et al. The relationship of aplastic anemia and PNH. Int J Hematol. 2002;76(Supplement 2):168\u201372.","journal-title":"Int J Hematol"},{"key":"2235_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.830172","volume":"12","author":"MA Colden","year":"2022","unstructured":"Colden MA, Kumar S, Munkhbileg B, Babushok DV. Insights into the emergence of paroxysmal nocturnal hemoglobinuria. Front Immunol. 2022;12:830172. https:\/\/doi.org\/10.3389\/fimmu.2021.830172.","journal-title":"Front Immunol"},{"key":"2235_CR24","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1073\/pnas.94.16.8756","volume":"94","author":"RA Brodsky","year":"1997","unstructured":"Brodsky RA, Vala MS, Barber JP, Medof ME, Jones RJ. Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA. 1997;94:8756\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2235_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF02983208","volume":"77","author":"N Inoue","year":"2003","unstructured":"Inoue N, Murakami Y, Kinoshita T. Molecular genetics of paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2003;77:107\u201312.","journal-title":"Int J Hematol"},{"key":"2235_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","volume":"83","author":"J Nishimura","year":"2004","unstructured":"Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193\u2013207.","journal-title":"Medicine (Baltimore)"},{"key":"2235_CR27","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","volume":"112","author":"RP de Latour","year":"2008","unstructured":"de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112:3099\u2013106.","journal-title":"Blood"},{"issue":"143","key":"2235_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1182\/blood.2023021762","volume":"21","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Holt M, Vidler J, Arnold LM, Large J, Forrest B, et al. Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria. Blood. 2024;21(143):1157\u201366.","journal-title":"Blood"},{"key":"2235_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cyto.b.20525","volume":"78B","author":"MJ Borowitz","year":"2010","unstructured":"Borowitz MJ, Craig FE, DiGiuseppe JA, Illingworth AJ, Rosse W, Sutherland R, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytom B Clin Cytom. 2010;78B:211\u201330.","journal-title":"Cytom B Clin Cytom"},{"key":"2235_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.b.20151","volume":"72","author":"DR Sutherland","year":"2007","unstructured":"Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo E, et al. Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytom B Clin Cytom. 2007;72:167\u201377.","journal-title":"Cytom B Clin Cytom"},{"key":"2235_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","volume":"97","author":"JW Lee","year":"2013","unstructured":"Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean registry. Int J Hematol. 2013;97:749\u201357.","journal-title":"Int J Hematol"},{"key":"2235_CR32","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","volume":"106","author":"C Parker","year":"2005","unstructured":"Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699\u2013709.","journal-title":"Blood"},{"key":"2235_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2141.2004.04992.x","volume":"126","author":"VM Moyo","year":"2004","unstructured":"Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126:133\u20138.","journal-title":"Br J Haematol"},{"key":"2235_CR34","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.293.13.1653","volume":"293","author":"RP Rother","year":"2005","unstructured":"Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653\u20131562.","journal-title":"JAMA"},{"key":"2235_CR35","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1056\/NEJMoa035477","volume":"350","author":"MT Gladwin","year":"2004","unstructured":"Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886\u201395.","journal-title":"N Engl J Med"},{"key":"2235_CR36","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Muus P, Soci\u00e9 G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99:922\u20139.","journal-title":"Haematologica"},{"key":"2235_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21757","volume":"85","author":"P Hillmen","year":"2010","unstructured":"Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85:553\u20139.","journal-title":"Am J Hematol"},{"issue":"1","key":"2235_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood.V57.1.83.83","volume":"57","author":"DA Clark","year":"1981","unstructured":"Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood. 1981;57(1):83\u20139.","journal-title":"Blood"},{"key":"2235_CR39","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","volume":"121","author":"A Hill","year":"2013","unstructured":"Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985\u201396.","journal-title":"Blood"},{"key":"2235_CR40","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1182\/blood-2003-01-0009","volume":"102","author":"C Hall","year":"2003","unstructured":"Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587\u201391.","journal-title":"Blood"},{"key":"2235_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0161-5890(03)00111-1","volume":"40","author":"BP Morgan","year":"2003","unstructured":"Morgan BP, Harris CL. Complement therapeutics: history and current progress. Mol Immunol. 2003;40:159\u201370.","journal-title":"Mol Immunol"},{"key":"2235_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1568010043483890","volume":"3","author":"M Mizuno","year":"2004","unstructured":"Mizuno M, Morgan BP. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases. Curr Drug Targets Inflamm Allergy. 2004;3:87\u201396.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"2235_CR43","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2005-02-0782","volume":"107","author":"A Hill","year":"2006","unstructured":"Hill A, Ridley SH, Esser D, Oldroyd RG, Cullen MJ, Kareclas P, et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood. 2006;107:2131\u20137.","journal-title":"Blood"},{"key":"2235_CR44","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood.V84.8.2604.2604","volume":"84","author":"RP Rother","year":"1994","unstructured":"Rother RP, Rollins SA, Mennone J, Chodera A, Fidel SA, Bessler M, et al. Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement. Blood. 1994;84:2604\u201311.","journal-title":"Blood"},{"issue":"5","key":"2235_CR45","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2005-02-0782","volume":"107","author":"A Hill","year":"2006","unstructured":"Hill A, Ridley SH, Esser D, Oldroyd RG, Cullen MJ, Kareclas P, et al. Protection of erythrocytes from human complement\u2013mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood. 2006;107(5):2131\u20137.","journal-title":"Blood"},{"key":"2235_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00005792-198409000-00001","volume":"63","author":"SC Ross","year":"1984","unstructured":"Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore). 1984;63:243\u201373.","journal-title":"Medicine (Baltimore)"},{"key":"2235_CR47","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256\u201364.","journal-title":"Nat Biotechnol"},{"key":"2235_CR48","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New Engl J Med. 2004;350:552\u20139.","journal-title":"New Engl J Med"},{"key":"2235_CR49","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233\u201343.","journal-title":"N Engl J Med"},{"issue":"4","key":"2235_CR50","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840\u20137.","journal-title":"Blood"},{"key":"2235_CR51","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","volume":"110","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Muus P, D\u00fchrsen U, Risitano AM, Schubert J, Luzzatto L, et al. \u2660Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123\u20138.","journal-title":"Blood"},{"key":"2235_CR52","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786\u201392.","journal-title":"Blood"},{"key":"2235_CR53","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, F\u00fcreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133:530\u20139.","journal-title":"Blood"},{"key":"2235_CR54","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540\u20139.","journal-title":"Blood"},{"key":"2235_CR55","first-page":"81","volume":"104","author":"A Kulasekararaj","year":"2025","unstructured":"Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, R\u00f6th A, Piatek C, et al. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2025;104:81\u201394.","journal-title":"Ann Hematol"},{"key":"2235_CR56","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/ajh.27413","volume":"99","author":"P Scheinberg","year":"2024","unstructured":"Scheinberg P, Cl\u00e9 DV, Kim JS, Nur E, Yenerel MN, Barcellini W, et al. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2024;99:1757\u201367.","journal-title":"Am J Hematol"},{"key":"2235_CR57","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/ajh.27412","volume":"99","author":"A R\u00f6th","year":"2024","unstructured":"R\u00f6th A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, et al. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. Am J Hematol. 2024;99:1768\u201377.","journal-title":"Am J Hematol"},{"key":"2235_CR58","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/ajh.26998","volume":"98","author":"H Liu","year":"2023","unstructured":"Liu H, Xia L, Weng J, Zhang F, He C, Gao S, et al. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): a multicenter, phase 3, single-arm study. Am J Hematol. 2023;98:1407\u201314.","journal-title":"Am J Hematol"},{"issue":"144","key":"2235_CR59","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2024-194610","volume":"5","author":"C Patriquin","year":"2024","unstructured":"Patriquin C, Jang JH, Aurand L, Taneja D, Magyar A, Dain B, et al. Efficacy and safety of pozelimab plus cemdisiran vs ravulizumab in patients with paroxysmal nocturnal hemoglobinuria who are na\u00efve to complement inhibition. Blood. 2024;5(144):306.","journal-title":"Blood"},{"key":"2235_CR60","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1002\/ajh.27456","volume":"99","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Lanza F, Arvanitakis A, Langemeijer S, Chonat S, Tombak A, et al. Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2024;99:2108\u201317.","journal-title":"Am J Hematol"},{"key":"2235_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jha2.632","volume":"4","author":"JH Jang","year":"2022","unstructured":"Jang JH, Gomez RD, Bumbea H, Nogaieva L, Wong LLL, Lim SM, et al. A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EJHaem. 2022;4:26\u201336.","journal-title":"EJHaem"},{"issue":"Supplement 1","key":"2235_CR62","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/blood-2019-127005","volume":"134","author":"CJ Patriquin","year":"2019","unstructured":"Patriquin CJ, Kulasekararaj A, Peffault de Latour R, Jang J-H, Langemeijer S, Maschan AA, et al. Prophylactic antibiotic use and risk of meningococcal infections in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab who received meningococcal vaccination: Results from the International PNH Registry. Blood. 2019;134(Supplement 1):4802.","journal-title":"Blood"},{"key":"2235_CR63","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","volume":"101","author":"D Dingli","year":"2022","unstructured":"Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Yeh M, Fishman J, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101:251\u201363.","journal-title":"Ann Hematol"},{"key":"2235_CR64","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","volume":"113","author":"AM Risitano","year":"2009","unstructured":"Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094\u2013100.","journal-title":"Blood"},{"key":"2235_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102416","volume":"8","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Nishimori H, Horneff R, Hillmen P, Al-Adhami M, Lallier S, et al. Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings. Res Pract Thromb Haemost. 2024;8:102416.","journal-title":"Res Pract Thromb Haemost"},{"key":"2235_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04903-x","author":"RSM Wong","year":"2022","unstructured":"Wong RSM, Pullon HWH, Amine I, Bogdanovic A, Deschatelets P, Francois CG, et al. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2022. https:\/\/doi.org\/10.1007\/s00277-022-04903-x.","journal-title":"Ann Hematol"},{"key":"2235_CR67","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","volume":"7","author":"RSM Wong","year":"2023","unstructured":"Wong RSM, Navarro-Cabrera JR, Comia NS, Goh YT, Idrobo H, Kongkabpan D, et al. Pegcetacoplan controls hemolysis in complement inhibitor-na\u00efve patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023;7:2468\u201378.","journal-title":"Blood Adv"},{"key":"2235_CR68","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, R\u00f6th A, H\u00f6chsmann B, Panse J, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384:1028\u201337.","journal-title":"N Engl J Med"},{"key":"2235_CR69","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/ajh.27242","volume":"99","author":"M Griffin","year":"2024","unstructured":"Griffin M, Kelly R, Brindel I, Maafa L, Trikha R, Muus P, et al. Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2024;99:816\u201323.","journal-title":"Am J Hematol"},{"key":"2235_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/hematolrep16040065","volume":"16","author":"B Mulherin","year":"2024","unstructured":"Mulherin B, Shenoy A, Arnett L, Jiao W, Guarinoni J, Sarda S, et al. Real-world study of US adults with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan. Hematol Rep. 2024;16:669\u201381.","journal-title":"Hematol Rep"},{"key":"2235_CR71","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","volume":"6","author":"JH Jang","year":"2022","unstructured":"Jang JH, Wong L, Ko BS, Yoon SS, Li K, Baltcheva I, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6:4450\u201360.","journal-title":"Blood Adv"},{"key":"2235_CR72","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","volume":"8","author":"AM Risitano","year":"2021","unstructured":"Risitano AM, R\u00f6th A, Soret J, Frieri C, de Fontbrune FS, Marano L, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof- of-concept trial. Lancet Haematol. 2021;8:e344\u201354.","journal-title":"Lancet Haematol"},{"key":"2235_CR73","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","volume":"390","author":"R Peffault de Latour","year":"2024","unstructured":"Peffault de Latour R, R\u00f6th A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, et al. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2024;390:994\u20131008.","journal-title":"N Engl J Med"},{"issue":"6","key":"2235_CR74","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S2352-3026(25)00081-X","volume":"12","author":"AM Risitano","year":"2025","unstructured":"Risitano AM, Kulasekararaj AG, Scheinberg P, R\u00f6th A, Han B, Maciejewski JP, et al. Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors. Lancet Haematol. 2025;12(6):e414\u201330.","journal-title":"Lancet Haematol"},{"key":"2235_CR75","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3324\/haematol.2020.261826","volume":"106","author":"AM Risitano","year":"2021","unstructured":"Risitano AM, Kulasekararaj AG, Lee JW, Maciejewski JP, Notaro R, Brodsky R, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106:3188\u201397.","journal-title":"Haematologica"},{"key":"2235_CR76","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.2021011388","volume":"138","author":"AG Kulasekararaj","year":"2021","unstructured":"Kulasekararaj AG, Risitano AM, Maciejewski JP, Notaro R, Browett P, Lee JW, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021;138:1928\u201338.","journal-title":"Blood"},{"key":"2235_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00315-0","volume":"10","author":"JW Lee","year":"2023","unstructured":"Lee JW, Griffin M, Kim JS, Lee LLW, Piatek C, Nishimura JI, et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023;10:e955\u2013e965.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"2235_CR78","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1182\/blood-2024-205866","volume":"144","author":"M Griffin","year":"2024","unstructured":"Griffin M, Kelly RJ, Gavillet M, Muus P, H\u00f6chsmann B, Cummings WJ, et al. Monotherapy treatment with zaltenibart (OMS906), an alternative pathway Masp-3 inhibitor, improved key hematologic parameters in patients with PNH with a suboptimal response to ravulizumab: interim results from a phase 2 proof-of-concept study. Blood. 2024;144(Supplement 1):4072.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2235_CR79","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood-2024-210086","volume":"144","author":"F Zang","year":"2024","unstructured":"Zang F, Zang L, Yang C, Yue C, Ma J, He C, et al. KP104, a bifunctional C5 Mab-Factor H Fusion Protein, demonstrates sustained long-term efficacy and safety in complement inhibitor-na\u00efve PNH patients: updated results from a phase 2 study at 36\/38 weeks of obd treatment. Blood. 2024;144(Supplement 1):2699.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02235-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:03:19Z","timestamp":1761717799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02235-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":79,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02235-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RK: Alexion, Astra-Zeneca Rare Diseases: Speaker bureau, advisory boards and honoraria; Florio: honoraria; Novartis: research funding (to institute), speaker bureau, advisory boards and honoraria; Omeros: honoraria; Otsuka: honoraria; Roche: advisory boards and honoraria; Sobi: research funding (to institute), speaker bureau, advisory boards and honoraria. MH: Sobi: Research funding and honoraria; Novartis: honoraria; Alexion, Astra-Zeneca Rare Diseases: travel support. JS: Sobi: Speaker bureau, advisory board, honoraria and travel support; Alexion, Astra-Zeneca Rare Diseases: honoraria and speaker bureau; Novartis: advisory board, speaker, honoraria and travel support; Eli Lilly, honoraria; Takeda, honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable: data used to prepare this manuscript were all available in the published literature and references to data form the reference list.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"All authors participated equally in sourcing the data, writing the manuscript and correcting the manuscript. MH developed the figures.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}